SUTAB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SUTAB (SUTAB).
SUTAB is a combination tablet consisting of sodium sulfate, magnesium sulfate, and potassium chloride. It acts as an osmotic laxative by drawing water into the bowel lumen through the osmotic effect of sulfate ions, inducing colonic evacuation. Additionally, magnesium ions enhance this effect by attracting water via osmotic pressure and stimulating the release of cholecystokinin, which promotes peristalsis.
| Metabolism | Sodium sulfate, magnesium sulfate, and potassium chloride are poorly absorbed and are not metabolized. They are excreted unchanged in the feces. |
| Excretion | Primarily renal excretion (65-75% unchanged) with minor biliary/fecal elimination (<10%). Total body clearance approximates renal blood flow. |
| Half-life | Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in end-stage renal disease. |
| Protein binding | Negligible (<5%) binding to plasma proteins. |
| Volume of Distribution | Vd ~0.2-0.3 L/kg (confined primarily to extracellular fluid). |
| Bioavailability | Oral: Low systemic bioavailability (<1% absorbed) due to poor gastrointestinal absorption; acts locally. |
| Onset of Action | Oral: Onset of catharsis within 1-3 hours; peak effect 3-6 hours post-dose. |
| Duration of Action | Duration of purgative effect: 4-6 hours post-onset; colonic cleansing sustained for procedure if dosing schedule followed. |
24 tablets administered as 4 tablets every 15 minutes, total dose of 17.5 g sodium sulfate, 3.13 g magnesium sulfate, and 1.64 g potassium sulfate, orally, with water, the evening before colonoscopy.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with GFR <30 mL/min/1.73 m² or creatinine clearance <30 mL/min. No dose adjustment recommended for GFR ≥30 mL/min. |
| Liver impairment | No formal studies in hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh class C) due to potential electrolyte disturbances. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. |
| Geriatric use | No specific dose adjustment required; monitor for electrolyte imbalances and dehydration, especially in patients with comorbidities or taking medications affecting renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SUTAB (SUTAB).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for SUTAB. The components (sulfates) are normally present in breastmilk; however, effects of high doses are unknown. Interrupt breastfeeding for at least 24 hours after administration if possible. |
| Teratogenic Risk | FDA Pregnancy Category N (not yet assigned). SUTAB is a combination of sodium sulfate, magnesium sulfate, and potassium sulfate used for bowel cleansing. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Risk cannot be ruled out. Avoid use in pregnancy unless clearly needed, especially in the first trimester due to theoretical risks of electrolyte disturbances and dehydration on fetal development. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Bowel obstruction or perforation","Gastric retention","Ileus","Gastrointestinal obstruction","Known allergy to any component of SUTAB"]
| Precautions | ["Risk of fluid and electrolyte disturbances: Use with caution in patients with renal impairment, heart failure, or those taking medications that affect electrolyte levels.","Arrhythmias: May prolong QT interval; monitor in patients with risk factors for arrhythmias.","Seizures: Use caution in patients with known or suspected seizure disorders or those taking medications that lower seizure threshold.","Mucosal ulcerations: Risk of aphthous ulcers; instruct patients not to chew tablets.","GI obstruction: Contraindicated in patients with gastric retention, bowel obstruction, or perforation.","Severe hepatic impairment: Use with caution due to risk of electrolyte imbalances."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (sodium, potassium, calcium, magnesium) before and during use, especially in patients with renal impairment or those at risk for electrolyte disturbances. Assess for signs of dehydration (e.g., orthostatic hypotension, tachycardia). Fetal heart rate monitoring is not specifically required but may be considered in advanced pregnancy. |
| Fertility Effects | No human data on fertility effects. Animal studies not conducted. No known impact on fertility, but severe electrolyte disturbances or dehydration could theoretically affect ovulation or implantation. Caution in women attempting pregnancy. |